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Abstract: It has been hypothesized that
treating hypercholesterolemic patients with
statins will lead not only to a reduction in
cholesterol, but also to inhibited synthesis of
other compounds that derive from the
synthetic pathway of cholesterol. One
important by-product is ubiquinone (CQ),
which has a pivotal role in mitochondrial
electron transport and antioxidant activity.
We therefore investigated the effect of 2
months of simvastatin treatment (20 mg/day)
on blood ATP concentration, plasma total
antioxidant capacity and ubiquinone levels in
17 hypercholesterolemic patients (age range:
40 to 65). To evaluate the possible musclerelated side effects, plasma CK activity and
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Introduction
3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA)
reductase inhibitors, or statins, have been widely used to
lower hypercholesterolemia. They inhibit the conversion
of HMG-CoA to mevalonic acid, the second step in
cholesterol biosynthesis, and lower plasma cholesterol
(1,2). However, a number of studies have reported
possible psychiatric adverse effects and cancer associated
with cholesterol lowering (3,4). Other isoprene
compounds such as ubiquinone synthesized in the same
pathway may also be affected by statins (5).
An increase in psychiatric adverse effects and cancer
has been reported at low levels of cholesterol (4,5). Being
a member of the electron transport chain, ubiquinone
plays an important role in ATP synthesis, and, in its
reduced form, it protects membranes against free radical
damage with its antioxidant features (6,7). Therefore, its
reduced levels may be clinically relevant. Some authors
have suggested that, due to the role of ubiquinone in the
electron transport chain, treatment with statins would
also lead to a reduction in ATP production (8).
Although the major site of action of HMG CoA
reductase inhibitors in lowering serum cholesterol is the

myoglobin concentrations were compared
before and after therapy. We observed
decreased plasma ubiquinone levels and total
antioxidant capacity after two months of
therapy. CK activity and myoglobin
concentrations were increased in the treated
group. There was not statistically significant
difference for whole blood ATP levels.
It may be concluded that simvastatin lowers
plasma ubiquinone concentrations . The
possible adverse effect of simvastatin on
ubiquinone metabolism may be clinically
important and requires further study.
Key Words: Ubiquinone, HMG CoA reductase
inhibitors, ATP, antioxidant

hepatocyte, the lipophilic nature of simvastatin results in
decreased selectivity and uptake of the drug by various cell
types (9). Clinical evidence indicates a potential for skeletal
muscle toxicity including elevated creatine kinase levels,
myositis, and even rhabdomyolysis after therapy with HMG
CoA reductase inhibitors. Myopathy has been found,
especially during combination therapy with other drugs
such as gemfibrozil, cyclosporin and erythromycin (10).
The aim of this study was to determine the effects of
treatment with simvastatin, a potent HMG CoA reductase
inhibitor, on plasma ubiquinone, whole blood adenosine
triphosphate (ATP) levels, total antioxidant capacity and
muscle related markers at usual doses.

Materials and Methods
Subjects
Seventeen hypercholesterolemic men, aged 40 to 60
years, for whom simvastatin therapy was started by the
Dokuz Eylül University Medical Faculty Cardiology
Outpatient Clinic, volunteered for this study. Their plasma
total cholesterol concentrations ranged between 6.06 and
10.4 mmol/L. They were otherwise healthy and had never
received hypocholesterolemic or other drug therapy.
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They were instructed to adhere to their normal diet
and not to use vitamin supplements during the study. All
hypercholesterolemic patients received 20 mg simvastatin
nightly for 2 months. The blood samples were collected
before and after the treatment period.

of differences between groups was determined by
Wilcoxon paired test.

Fifteen apparently healthy men with a total plasma
cholesterol level below 5.8 mmol/L were selected as the
control group. They were age matched and took no
medications and had no signs of disease. The study was
approved by the ethical committee of the university and
all the men gave their informed consent.

After 2 months of treatment with simvastatin, plasma
total and LDL cholesterol levels decreased from
pretreatment levels on average by 29% and 38%
respectively (p < 0.001). In addition, a decrease in plasma
triglycerides (33%; p < 0.001) and a slight increase in
plasma HDL cholesterol (+8%; p = 0.18) were observed
(Table 1).

Laboratory methods
Fasting blood samples were drawn for lipid,
lipoprotein, ubiquinone, ATP, CK, myoglobin and total
antioxidant capacity determinations.

Lipid and lipoprotein analyses. The concentrations of
total cholesterol, HDL cholesterol and triglycerides in
plasma were determined using commercial kits
manufactured by Sigma Diagnostica. LDL cholesterol was
calculated using the Friedewald equation (11).
Ubiquinone. The ubiquinone assays were performed
by a high-performance liquid chromatographic method as
described by Grossi et al. (12), using a C-18 reversedphase column 5 µm(125 mm x 4.6 mm I.D.) and a mobile
phase of 2-propanol-methanol (1:4) with ultraviolet
detection at 275 nm.
ATP. Whole blood ATP levels (13) were measured
immediately after blood sampling. ATP analysis was
performed after deproteinization with trichloroaceticacid
with an enzymatic, colorimetric ATP assay kit from Sigma
Diagnostica.
Total antioxidant capacity (TAC). Plasma TAC was
measured using the ABTS (Azino-diethyl-benzthiazoline
sulfate) method (14) with a total antioxidant status kit
from Randox Laboratories Ltd.
CK. CK activity was measured with a quantitative,
kinetic kit manufactured by Sigma Diagnostica on a
Hitachi 747-200 autoanalyzer.
Myoglobin. Myoglobin analysis was performed with
an immunochemical method using myoglobin kits
manufactured by Boehringer Mannheim Diagnostica
(Mannheim, Germany) on an Elecsys-2010 autoanalyzer.
Statistical analysis
The SPSS program was used for statistical analyses.
The values were expressed as mean (SD). The significance
324

Results

In the simvastatin group, a decrease of 30% (p <
0.001) was detected in plasma total ubiquinone after 2
months of treatment, but these concentrations (0.90
mg/L) were still higher than those in the control group
(0.62 mg/L; p < 0.01) (Table 1). The close relationship
between ubiquinone(CQ) and cholesterol levels was
reflected by the constant CQ:total cholesterol and CQ:LDL
cholesterol ratios before and after therapy (Table 1).
There were no significant differences in blood ATP
levels before and after therapy while total antioxidant
capacity decreased after therapy (p < 0.01) (Table 2).
Significant increases were noted for plasma CK activity
(p < 0.001) and myoglobin concentrations (p < 0.001)
after therapy (Table 3 ).

Discussion
The results of our study showed that plasma
ubiquinone levels were significantly lower after the
hypercholesterolemic patients were treated with
simvastatin. Our results agree with previous studies
suggesting that serum ubiquinone levels are considerably
higher in patients with untreated hypercholesterolemia
than in normocholesterolaemic individuals (15,16). In
some previous studies, it has been reported that although
statin treatment lowers serum ubiquinone values, the
reduced values still remain at the same or even higher
levels than those of healthy normolipidemic subjects
(15,16). The results of the present study further support
this concept. The decrease in ubiquinone levels was
parallel to the decrease in total cholesterol and LDL
cholesterol as also reported in other studies (15,16). The
close relationship between plasma ubiquinone and
cholesterol levels was reflected by the invariable
ubiquinone-cholesterol relationship regardless whether
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Statin-treated group
Before treatment
(n = 17)
TC (mmol/L)
LDL-C (mmol/L)
HDL-C (mmol/L)
TG (mmol/L)
CQ (mg/L)
CQ/TC (mg/mmol)
CQ/LDL-C (mg/mmol)

7.25
4.90
1.24
2.57
1.28
0.17
0.26

(1.13)
(0.65)
(0.21)
(1.04)
(0.32)
(0.03)
(0.05)

After treatment
(n = 17)
5.14
3.01
1.35
1.72
0.90
0.17
0.29

(1.0)**
(0.75)**
(0.27)
(0.74)**
(0.31)**
(0.06)
(0.12)

Table 1.

Lipid, lipoprotein and ubiquinone
data in the statin-treated group and
control group.

Table 2.

ATP and total antioxidant capacity
data in the statin-treated group and
control group.

Table 3.

CK and myoglobin data in the
statin-treated group and control
group.

Control group
(n = 15)
4.50
2.79
1.18
1.24
0.62
0.14
0.23

(0.54)
(0.51)
(0.21)
(0.48)
(0.09)
(0.02)
(0.05)

TC = Plasma total cholesterol; LDL-C = Low-density lipoprotein cholesterol; HDL-C = Highdensity lipoprotein cholesterol; TG = Triglycerides; CQ = Ubiquinone
Mean (SD); **p < 0.001 for comparison between lipid and ubiquinone levels before and after
treatment.

Statin-treated group
Before treatment
(n = 17)

After treatment
(n = 17)

Control group
(n = 15)

ATP (µmol/dL)

54.24 (7.65)

55.32 (7.17)

57.38 (2.13)

TAC (mmol/L)

1.31 (0.28)

1.03 (0.30)*

1.12 (0.15)

ATP =Adenosine triphosphate;TAC = total antioxidant capacity
Mean (SD); *p < 0.01 for comparison between TAC levels before and after treatment.

Statin-treated group
Before treatment
(n = 17)
CK (U/L)

92.58 (45.23)

Myoglobin (ng/L)

38.74 (7.64)

After treatment
(n = 17)
113.5 (55.2)**
55.34 (16.47)**

Control group
(n = 15)
92.4 (30.3)
34.33 (3.56)

CK = Creatine kinase
Mean (SD); **p < 0.001 for comparison between CK and myoglobin

the patients were receiving statin or not. Furthermore,
these ratios in the normal control subjects were
comparable to those observed in the statin-treated
patients. The decrease in ubiquinone levels could either be
due to the inhibition of its biosynthesis or to the reduced
amounts of low density lipoproteins that transport it, or
both factors might have contributed to it.
Mainly based on findings of lowered serum
ubiquinone levels during statin treatment, it has been

hypothesized that mitochondrial generation of highenergy phosphates could be adversely affected in statintreated patients (17,18). An experimental study in
simvatatin-treated rats reported a decrease in blood ATP
levels but no impairment in muscle high-energy
phosphate metabolism (19). Similarly, Laaksonen et al.
reported that skeletal muscle high-energy phosphates did
not change in hypercholesterolemic patients receiving 6
months of simvastatin treatment (20). The results
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showed that whole blood ATP concentrations were not
affected following 2 months (20/mg/day) of simvastatin
therapy.
However, since ubiquinone is present in mitochondria
in molar amounts greatly exceeding those of other
respiratory chain carriers (21), the rate of ATP
production in long-term simvastatin-treated patients are
not clear yet and needs further investigation.
Muscle necrosis and high serum CK activities were
reported in simvastatin treated rabbits (22). Our results
also indicate that plasma CK and myoglobin
concentrations were increased after simvastatin therapy.
Several explanations for the increase in CK have been
proposed. It has been stated that ubiquinone deficiency
could result in a mitochondrial myopathy with reduced
mitochondrial ATP production and mitochondrial
dysfunction. Chariot has reported that a 63-year-old
female in whom simvastatin has induced rhabdomyolysis
and
mitochondrial myopathy and whose muscle
ubiquinone levels were below normal and symptoms
improved with ubiquinone replacement (23).
Another possible mechanism that can explain the
myopathy is that simvastatin interferes with muscle
cholesterol synthesis, eventually altering the lipid
composition and microviscosity of the membranes of
muscle cells. Simvastatin, like other lipophilic HMG CoA
reductase inhibitors, is not liver selective and enters cells
of various tissues like muscle tissues (24). Clinical
experience has shown that the concomitant use of other
drugs
(i.e.
macrolide
antibiotics
and
immunosuppressants) with simvastatin increase the risk
of myopathy (25,26). The findings of our study indicate
that the use of simvastatin alone and at usual doses leads
to increased CK and myoglobin levels. For this reason, it
may be concluded that patients treated with simvastatin
should be monitored for CK and myoglobin and if a
significant elevation is detected in patients using
simvastatin, the drug may be changed since highly tissue
selective drugs such as pravastatin are reported not to
induce muscle toxicity (27).
In addition to its well-established function as a
component of the mitochondrial respiratory chain,
ubiquinone has in recent years acquired increasing
attention with regard to its function in reduced form
(ubiquinol) as an antioxidant. Ubiquinol is the only known
lipid-soluble antioxidant that animal cells can synthesize

326

de novo. Its high degree of hydrophobicity and its
widespread occurrence in biological membranes and in
low-density lipoproteins suggest an important role of
ubiquinol in cellular defense against oxidative damage
(28). Ubiquinol is suggested to have an antioxidant
function both directly by radical scavenging and also
indirectly by acting as an electron donor for a-tocoperoxyl
radicals (a-TO.), thus providing endogenous tocopherol
(vitamin E) regeneration and enhancing overall
antioxidant activity in membranes (29,30). In our study,
we observed a significant decrease in TAC following
simvastatin therapy. This could be explained by the
decrease in ubiquinone related to the possible mechanism
discussed above. To our knowledge, this is the first study
of TAC in simvastatin-treated patients.
A number of studies have demonstrated a positive
correlation between low serum cholesterol levels and
noncardiovasculer deaths due to cancer, accidents, and
depression (31,32). However, this association has not
been explained yet. In recent larger clinical trials, these
early results were not confirmed (33,34). The presence
of such a connection remains controversial.
For patients with known coronary heart disease, the
recent Scandinavian Simvastatin Survival Study suggests
that the benefits of cholesterol lowering exceed the risks,
at least in men and in the short term (35).
However, decreased ubiquinone levels have been
reported in several diseases including neurodegenerative
diseases and cancer (36-39). It is also not clear yet
whether and to what extent these diseases are related to
an alteration of the bioenergetic capacity and/or of the
antioxidant status of the tissues concerned. Thus, it may
be questioned whether the decrease is responsible for the
adverse effects of lowered cholesterol levels in
simvastatin-treated patients.
In conclusion, our results show that simvastatin does
lower plasma ubiquinone levels, even in short-term
therapy. Because of its important role for human
organism we think that the supplementation of
simvastatin-treated patients with ubiquinone would be
benefical.
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